Apricus Biosciences Inc (APRI) - Financial and Strategic SWOT Analysis Review

  • ID: 4315243
  • SWOT Analysis
  • 48 pages
  • GlobalData
  • Apricus Biosciences Inc
1 of 5

FEATURED COMPANIES

  • Eli Lilly and Company
  • GlaxoSmithKline Inc
  • Meda Pharmaceuticals Inc
  • Pfizer Inc
  • MORE
Apricus Biosciences Inc (APRI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Apricus Biosciences Inc (Apricus) develops and commercializes pharmaceutical products indicated for the treatment of various therapeutic classes including urology and rheumatology. Its product pipeline includes, Vitaros (alprostadil), a topical vasodilator cream in-licensed from Warner Chilcott Inc. for the treatment of erectile dysfunction; and RayVa or alprostadil topical cream, product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon. The company develops these products using its proprietary permeation enhancement technology, namely, NexACT, designed to enhance delivery of an active drug to the patient. It operates along with its subsidiaries in British Virgin Islands, and the US. Apricus is headquartered in San Diego, California, the US.

Apricus Biosciences Inc Key Recent Developments

May 11,2017: Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results
Mar 13,2017: Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results
Jan 03,2017: Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel
Dec 01,2016: Apricus Biosciences Receives Nasdaq Compliance Notice
Nov 08,2016: Apricus Biosciences Provides Corporate Update and Third Quarter Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Eli Lilly and Company
  • GlaxoSmithKline Inc
  • Meda Pharmaceuticals Inc
  • Pfizer Inc
  • MORE
Section 1 - About the Company
Apricus Biosciences Inc - Key Facts
Apricus Biosciences Inc - Key Employees
Apricus Biosciences Inc - Key Employee Biographies
Apricus Biosciences Inc - Major Products and Services
Apricus Biosciences Inc - History
Apricus Biosciences Inc - Company Statement
Apricus Biosciences Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 - Company Analysis
Apricus Biosciences Inc - Business Description
Apricus Biosciences Inc - Corporate Strategy
Apricus Biosciences Inc - SWOT Analysis
SWOT Analysis - Overview
Apricus Biosciences Inc - Strengths
Apricus Biosciences Inc - Weaknesses
Apricus Biosciences Inc - Opportunities
Apricus Biosciences Inc - Threats
Apricus Biosciences Inc - Key Competitors

Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Apricus Biosciences Inc, Recent Deals Summary

Section 5 - Company’s Recent Developments
May 11, 2017: Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results
Mar 13, 2017: Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results
Jan 03, 2017: Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel
Dec 01, 2016: Apricus Biosciences Receives Nasdaq Compliance Notice
Nov 08, 2016: Apricus Biosciences Provides Corporate Update and Third Quarter Financial Results
Aug 04, 2016: Apricus Biosciences Provides Corporate Update and Second Quarter Financial Results
May 09, 2016: Apricus Biosciences Provides Corporate Update and First Quarter Financial Results
Mar 09, 2016: Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2015 Financial Results
Jan 06, 2016: Apricus Biosciences Announces Year-End 2015 Update and 2016 Growth Strategy

Section 6 - Appendix
Methodology
Ratio Definitions
About
Contact
Disclaimer

List of Tables
Apricus Biosciences Inc, Key Facts
Apricus Biosciences Inc, Key Employees
Apricus Biosciences Inc, Key Employee Biographies
Apricus Biosciences Inc, Major Products and Services
Apricus Biosciences Inc, History
Apricus Biosciences Inc, Subsidiaries
Apricus Biosciences Inc, Key Competitors
Apricus Biosciences Inc, Ratios based on current share price
Apricus Biosciences Inc, Annual Ratios
Apricus Biosciences Inc, Annual Ratios (Cont...1)
Apricus Biosciences Inc, Interim Ratios
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Apricus Biosciences Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Apricus Biosciences Inc, Performance Chart (2012 - 2016)
Apricus Biosciences Inc, Ratio Charts
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Pfizer Inc
  • Metuchen Pharmaceuticals LLC
  • Meda Pharmaceuticals Inc
  • GlaxoSmithKline Inc
  • Eli Lilly and Company
  • Auxilium Pharmaceuticals LLC
  • A. Menarini Industrie Farmaceutiche Riunite Srl
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll